Ga direct naar de inhoud

Ga direct naar de navigatie

Uitgave van

Berichten met het trefwoord ‘Amgen’

Amgen wins European approval for Humira biosimilar Amgevita

The European Commission has approved Amgen’s biosimilar version of AbbVie’s $16.1bn-a-year autoimmune disease treatment Humira (adalimumab). Amgevita (biosimilar adalimumab) is both Amgen’s first biosimilar and now the first Humira biosimilar to be approved in Europe.

Bron: PMLiVE Meer lezen »

Sanofi, Regeneron ask court to shield Dupixent from Amgen patent attack

The last time Sanofi and Regeneron launched a drug together, Amgen sued for patent infringement. Now, with an FDA decision on their key drug Dupixent due next week, the development partners are making a pre-emptive strike in patent court. Sanofi and Regeneron sued Amgen on Monday, seeking a declaration that Dupixent, also known as dupilumab, […]

Bron: FiercePharma Meer lezen »

Data on heart benefits of Amgen drug is key to unlocking sales

Data that should help unlock the sales potential of a potent new cholesterol medicine will be unveiled at the American College of Cardiology meeting this week as the future of the only rival drug rests with the courts in an ongoing patent dispute.

Bron: Reuters Meer lezen »

Amgen drug pair become first Humira biosimilars to win EU approval

Good news for Amgen as its two biosimilar versions of AbbVie’s blockbuster rheumatoid arthritis (RA) drug Humira (adalimumab) have been awarded recommendation for approval by the European Medicines Agency (EMA) for the treatment of moderate to severe RA in patients who have not responded to methotrexate or have not been previously treated with it.

Bron: InPharm.com Meer lezen »

Amgen and Immatics enter $1bn immuno-oncology partnership

Amgen has announced it is to join forces with cancer immunotherapy biotech Immatics Biotechnologies in a partnership potentially worth over $1 billion to develop and commercialise T-cell engaging bispecific cancer immunotherapies.

Bron: InPharm.com Meer lezen »

Amgen’s Kyprolis disappoints in Phase III trial

Amgen was relying on the results of the trial to justify its $10.4 billion purchase of Onyx Pharmaceuticals, acquiring Kyprolis at the same time, and needed strong data in terms of progression-free survival.

Bron: InPharm.com Meer lezen »

Amgen’s multiple myeloma drug falls short in late stage study

Amgen Inc said on Tuesday its cancer drug Kyprolis failed to meet the main goal of a late-stage study against Takeda Pharmaceutical Co Ltd’s Velcade for treating newly diagnosed multiple myeloma.

Bron: Reuters Meer lezen »

Positive Phase III results for Amgen’s Repatha for coronary artery disease

Amgen has announced that its monoclonal antibody Repatha (evolocumab) achieved positive Phase III results for the treatment of coronary artery disease (CAD), meeting its primary and secondary endpoints.  

Bron: InPharm.com Meer lezen »

Amgen obtains global development and commercial rights from Boehringer Ingelheim for investigational BiTE® immuno-oncology drug for multiple myeloma

Amgen (NASDAQ:AMGN) and Boehringer Ingelheim today announced that Amgen has acquired global development and commercial rights from Boehringer Ingelheim for BI 836908 (AMG 420), a bispecific T cell engager (BiTE®) that targets B-cell maturation antigen (BCMA), a potential target for multiple myeloma.

Bron: World Pharma News Meer lezen »

Amgen enters into $540m immunotherapy collaboration

Amgen has bought into a preclinical cancer immunotherapy treatment developed by small US biotech Advaxis, in a deal potentially worth $540m.

Bron: PMLiVE Meer lezen »

« Oudere artikelen |